Please wait a minute...
J Zhejiang Univ (Med Sci)  2021, Vol. 50 Issue (4): 524-528    DOI: 10.3724/zdxbyxb-2021-0156
New-onset and relapsing glomerular diseases related to COVID-19 vaccination
LIU Fei(),FENG Chunyue,MAO Jianhua,FU Haidong()
Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children’s Regional Medical Center, Hangzhou 310052, China
Download: HTML( 10 )   PDF(1979KB)
Export: BibTeX | EndNote (RIS)      


COVID-19 vaccine, as one of the critical measures to control the pandemic, has been administered in nearly all countries. However, the new-onset and relapsing glomerular diseases associated with COVID-19 vaccination have become a new concern. Both mRNA vaccine and inactivated vaccine may cause new-onset and relapsing glomerular diseases; these diseases would occur after the first dose vaccination or the second dose. New-onset glomerular disease is mainly minimal change glomerulopathy, which is mostly sensitive to steroid, while relapsing cases have good prognosis, and some cases can be spontaneously remitted. The pathogenesis of these vaccine-associated diseases is possibly due to the humoral and cellular immune responses. In this article, we provide a general review of the new-onset and relapsing glomerular diseases related to COVID-19 vaccination, and make suggestions for patients with kidney diseases to receive COVID-19 vaccination.

Key wordsCoronavirus disease 2019      Vaccines      Adverse reaction      Glomerulopathy      New-onset      Relapsing      Review     
Received: 02 June 2021      Published: 01 November 2021
CLC:  R511  
Corresponding Authors: FU Haidong     E-mail:;
Cite this article:

LIU Fei,FENG Chunyue,MAO Jianhua,FU Haidong. New-onset and relapsing glomerular diseases related to COVID-19 vaccination. J Zhejiang Univ (Med Sci), 2021, 50(4): 524-528.

URL:     OR



关键词: 2019冠状病毒病,  疫苗,  不良反应,  肾小球病,  新发,  复发,  综述 
[1]   LIY, TENCHOVR, SMOOTJ, et al.A comprehensive review of the global efforts on COVID-19 vaccine development[J]ACS Cent Sci, 2021, 7( 4): 512-533.
doi: 10.1021/acscentsci.1c00120
[2]   World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines[EB/OL]. [2021-05-25].
[3]   CARNEIROD C, SOUSAJ D, MONTEIRO-CUNHAJ P. The COVID-19 vaccine development: a pandemic paradigm[J]Virus Res, 2021, 198454.
doi: 10.1016/j.virusres.2021.198454
[4]   SCHULTZN H, S?RVOLLI H, MICHELSENA E, et al.Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination[J]N Engl J Med, 2021, 384( 22): 2124-2130.
doi: 10.1056/NEJMoa2104882
[5]   BOZKURTB, KAMATI, HOTEZP J. Myocarditis with COVID-19 mRNA vaccines[J]Circulation, 2021, 144( 6): 471-484.
doi: 10.1161/CIRCULATIONAHA.121.056135
[6]   CASTELLSM C, PHILLIPSE J. Maintaining safety with SARS-CoV-2 vaccines[J]N Engl J Med, 2021, 384( 7): 643-649.
doi: 10.1056/NEJMra2035343
[7]   FORMEISTERE J, CHIENW, AGRAWALY, et al.Preliminary analysis of association between COVID-19 vaccination and sudden hearing loss using US centers for disease control and prevention vaccine adverse events reporting system data[J]JAMA Otolaryngol Head Neck Surg, 2021, 147( 7): 674-676.
doi: 10.1001/jamaoto.2021.0869
[8]   LEBEDEVL, SAPOJNIKOVM, WECHSLERA, et al.Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine[J]Am J Kidney Dis, 2021, 78( 1): 142-145.
doi: 10.1053/j.ajkd.2021.03.010
[9]   D’AGATIV D, KUDOSES, BOMBACKA S, et al.Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine[J]Kidney Int, 2021, 100( 2): 461-463.
doi: 10.1016/j.kint.2021.04.035
[10]   MAASR J, GIANOTTENS, VAN DER MEIJDENW A G. An additional case of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine[J]Am J Kidney Dis, 2021, 78( 2): 312.
doi: 10.1053/j.ajkd.2021.05.003
[11]   HOLZWORTHA, COUCHOTP, CRUZ-KNIGHTW, et al.Minimal change disease following the moderna mRNA-1273 SARS-CoV-2 vaccine[J]Kidney Int, 2021, 100( 2): 463-464.
doi: 10.1016/j.kint.2021.05.007
[12]   AYD?NM F, Y?LD?ZA, ORU?A, et al.Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination[J]Kidney Int, 2021, 100( 2): 464-465.
doi: 10.1016/j.kint.2021.05.001
[13]   KERVELLAD, JACQUEMONTL, CHAPELET-DEBOUTA, et al.Minimal change disease relapse following SARS-CoV-2 mRNA vaccine[J]Kidney Int, 2021, 100( 2): 457-458.
doi: 10.1016/j.kint.2021.04.033
[14]   KOMABAH, WADAT, FUKAGAWAM. Relapse of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine[J]Am J Kidney Dis, 2021, 78( 3): 469-470.
doi: 10.1053/j.ajkd.2021.05.006
[15]   RAHIMS E G, LINJ T, WANGJ C. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination[J]Kidney Int, 2021, 100( 1): 238.
doi: 10.1016/j.kint.2021.04.024
[16]   NEGREAL, ROVINB H. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy[J]Kidney Int, 2021, 99( 6): 1487.
doi: 10.1016/j.kint.2021.03.002
[17]   XUS, YANGK, LIR, et al.mRNA vaccine era—mechanisms, drug platform and clinical prospection[J]Int J Mol Sci, 2020, 21( 18): 6582.
doi: 10.3390/ijms21186582
[18]   SAHINU, MUIKA, DERHOVANESSIANE, et al.COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses[J]Nature, 2020, 586( 7830): 594-599.
doi: 10.1038/s41586-020-2814-7
[19]   VIVARELLI M, MASSELLA L, RUGGIERO B, et al. Minimal change disease[J]. Clin J Am Soc Nephrol, 2017, 12(2): 332-345
[20]   KIELSTEIN J T, TERMüHLEN L, SOHN J, et al. Minimal change nephrotic syndrome in a 65-year-old patient following influenza vaccination[J]. Clin Nephrol, 2000, 54(3): 246-248
[21]   GUTIERREZ S, DOTTO B, PETITI J P, et al. Minimal change disease following influenza vaccination and acute renal failure: just a coincidence?[J]. Nefrologia, 2012, 32(3): 414-415
[22]   LAMBERTE M, LIEBLINGA, GLUSACE, et al.Henoch-schonlein purpura following a meningococcalvaccine[J/OL]Pediatrics, 2003, 112( 6): e491-e494.
doi: 10.1542/peds.112.6.e491
[23]   MCNALLYA, MCGREGORD, SEARLEM, et al.Henoch-Schonlein purpura in a renal transplant recipient with prior IgA nephropathy following influenza vaccination[J]Clin Kidney J, 2013, 6( 3): 313-315.
doi: 10.1093/ckj/sft029
[24]   SEGALY, SHOENFELDY. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction[J]Cell Mol Immunol, 2018, 15( 6): 586-594.
doi: 10.1038/cmi.2017.151
[25]   SETTEA, CROTTYS. Adaptive immunity to SARS-CoV-2 and COVID-19[J]Cell, 2021, 184( 4): 861-880.
doi: 10.1016/j.cell.2021.01.007
[26]   SOYM, KESERG, ATAGUNDUZP, et al.A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review[J]Clin Rheumatol, 2021, 40( 9): 3533-3545.
doi: 10.1007/s10067-021-05700-z
[27]   DAL-RéR, BEKKERL G, GLUUDC, et al.Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities[J]Lancet Infect Dis, 2021,
doi: 10.1016/S1473-3099(21)00263-2
[28]   KRONBICHLERA, ANDERSH J, FERNANDEZ-JUáREZG M, et al.Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases[J]Nephrol Dial Transplant, 2021, 36( 7): 1160-1168.
doi: 10.1093/ndt/gfab064
[29]   中华医学会感染病学分会, 中华医学会风湿病学分会. 特殊人群(慢性肝病、结核病和风湿免疫病患者)新型冠状病毒疫苗接种专家建议[J]. 中华传染病杂志, 2021, 39(7): 398-403
Chinese Society of Infectious Diseases, Chinese Society of Rheumatology. Expert recommendation on severe acute respiratory syndrome coronavirus 2 vaccination in patients with chronic liver diseases, tuberculosis or rheumatoid diseases[J]. Chinese Journal of Infectious Diseases, 2021, 39(7): 398-403. (in Chinese)
[1] TANG Yue,KONG Yuanyuan. Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment[J]. J Zhejiang Univ (Med Sci), 2021, 50(4): 514-523.
[2] HAN Lianshu. Genetic screening techniques and diseases for neonatal genetic diseases[J]. J Zhejiang Univ (Med Sci), 2021, 50(4): 429-435.
[3] HU Jingyi,WANG Qingqing,LIU Yang. Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma[J]. J Zhejiang Univ (Med Sci), 2021, 50(3): 396-402.
[4] GE Yingzhou,LIU Xinmei,HUANG Hefeng. Advances in the role of silence information regulator family in pathological pregnancy[J]. J Zhejiang Univ (Med Sci), 2021, 50(3): 335-344.
[5] WANG Jintao,HUANG Lei,WEI Lili,CHEN Wei. Factors affecting the efficacy of repetitive transcranial magnetic stimulation for patients with Alzheimer’s disease[J]. J Zhejiang Univ (Med Sci), 2021, 50(3): 383-389.
[6] ZHUANG Wenwen,YANG Yongqi,LI Hongliang,LIANG Jingyan. Research advance of Nrf2 on atherosclerosis by regulating vascular smooth muscle cell[J]. J Zhejiang Univ (Med Sci), 2021, 50(3): 390-395.
[7] ZHU Feng,XIANG Yingchun,ZENG Linghui. Progress on mitochondrial silence information regulator family in epilepsy[J]. J Zhejiang Univ (Med Sci), 2021, 50(3): 403-408.
[8] KUANG Wenjing,LUO Xiaobo,WANG Jiongke,ZENG Xin. Research progress on Melkersson-Rosenthal syndrome[J]. J Zhejiang Univ (Med Sci), 2021, 50(2): 148-154.
[9] WANG Chenyu,WANG Yingnan,WANG Cunyi,SHI Jiejun,WANG Huiming. Research progress on tissue engineering in repairing temporo-mandibular joint[J]. J Zhejiang Univ (Med Sci), 2021, 50(2): 212-221.
[10] WU Yi,JIANG Weiliang,YANG Xiaojun,LI Wenhua,WAN Rong,LU Lungen,FAN Junwei,LU Zhanjun. Postoperative serum triglyceride levels in predicting risk of new-onset diabetes mellitus in patients following liver transplantation[J]. J Zhejiang Univ (Med Sci), 2021, 50(2): 239-244.
[11] REN Chaojie,ZHONG Danni,ZHOU Min. Research progress on the biomedical application of microalgae[J]. J Zhejiang Univ (Med Sci), 2021, 50(2): 261-266.
[12] YING Yingchao,JIANG Peifang. Research progress on transient receptor potential melastatin 2 channel in nervous system diseases[J]. J Zhejiang Univ (Med Sci), 2021, 50(2): 267-276.
[13] HAN Hengyi,FENG Fan,LI Haitao. Research advances on epigenetics and cancer metabolism[J]. J Zhejiang Univ (Med Sci), 2021, 50(1): 1-16.
[14] CHEN Fei,YU Min,ZHONG Yonghong,HUA Wen,HUANG Huaqiong. The role of neutrophils in asthma[J]. J Zhejiang Univ (Med Sci), 2021, 50(1): 123-130.
[15] YAN Jing,ZHANG Tingting,ZHAO Kui. Application of molecular probes in nuclear imaging of neuroendocrine tumors[J]. J Zhejiang Univ (Med Sci), 2021, 50(1): 131-137.